Expand Energy Corporation Common Stock vs Cassava Sciences Inc — how do they compare? Expand Energy Corporation Common Stock trades at $91.6 (market cap $21.38B), while Cassava Sciences Inc trades at $0.71 (market cap $35.91M). The key difference: Expand Energy Corporation Common Stock is far larger — about 595.4× Cassava Sciences Inc's market cap, and Expand Energy Corporation Common Stock pays a 2.49% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expand Energy Corporation Common Stock for 0 Days and Cassava Sciences Inc for 38 Days on average.
| EXE | FLNA | |
|---|---|---|
Market Cap | $21.38B | $35.91M |
Volume | 3,544,570 | 323,246 |
Sector | Energy | Health |
52-Week High | $122.89 | $4.64 |
52-Week Low | $84.09 | $0.68 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $24.45B | -$46.77M |
Dividend Yield | 2.49% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLNA trades at $0.7316, down 4.93% today, amid bearish technical signals despite recent FDA progress. The stock shows negative profitability with ROE at -55.79% and consistent negative cash flow, though it has beaten EPS estimates for three consecutive quarters. Analyst consensus remains positive with 8 buy ratings versus 4 holds.
The outlook hinges on clinical development success, particularly the Phase 2a study for TSC-related epilepsy. Investment opportunity exists if trials progress favorably, but risks include cash burn, regulatory hurdles, and persistent losses. Current valuation metrics like EV/EBITDA of 1.11 suggest potential upside if execution improves.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Expand Energy Corporation is a US natural gas producer formed from the 2024 merger of Chesapeake Energy and Southwestern Energy, developing gas assets concentrated in the Appalachia and Haynesville basins.
Read more on EXE →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →